Status:
TERMINATED
A Study to Evaluate the My Hematology Oncology Patient Experience (MyHOPE™) For Multiple Myeloma (MM) Digital Care Network in Patients With MM
Lead Sponsor:
Celgene
Collaborating Sponsors:
Amalgam Rx
Conditions:
Multiple Myeloma
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
NDS-MM-004 is a multi-center, randomized, pilot trial to evaluate the MyHOPE for multiple myeloma (MM) Platform in patients with MM. The MyHOPE for MM Platform is a validated investigational device ma...
Eligibility Criteria
Inclusion
- Patient is ≥ 18 years old with a diagnosis of Multiple Myeloma
- Patient must reside in the USA.
- Patients within each of the following subgroups, at one of the following timepoints, will be eligible for entry:
- Newly-diagnosed multiple myeloma transplant-eligible
- Patients undergoing their first ASCT
- Newly-diagnosed multiple myeloma transplant-ineligible
- Relapsed and/or refractory.
Exclusion
- Patient has a condition(s) that, in the opinion of the Investigator, would make participation infeasible such as inability to provide informed consent, illiteracy, or inability to speak, read, and write in English.
- Patient is on hospice.
- Patient is receiving or has received an investigational agent \< 28 days prior to randomization or during this pilot study.
Key Trial Info
Start Date :
February 4 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 21 2021
Estimated Enrollment :
2 Patients enrolled
Trial Details
Trial ID
NCT04730505
Start Date
February 4 2021
End Date
June 21 2021
Last Update
August 9 2021
Active Locations (34)
Enter a location and click search to find clinical trials sorted by distance.
1
Mitchell Cancer Center, University of South Alabama
Mobile, Alabama, United States, 36604
2
Mayo Cliinic - Scottsdale
Scottsdale, Arizona, United States, 85259
3
University of Arizona
Tucson, Arizona, United States, 85724-507
4
James R Berenson MD Inc
West Hollywood, California, United States, 90069